上海交大最新Science子刊论文：CAR-T治疗实体瘤新思路

Core Viewpoint - CAR-T cell therapy has shown remarkable efficacy in treating B-cell malignancies, but its effectiveness in solid tumors remains limited due to poor infiltration capabilities [2][3]. Group 1: Research Findings - The study published by Professor Yang Xuanming's team reveals that co-stimulation via OX40 significantly enhances CAR-T cell anti-tumor activity against solid tumors, including pancreatic, breast, and lung cancers [3][5]. - Heparan sulfate (HS) is identified as a ligand for OX40, promoting CAR-T cell infiltration and persistence in solid tumors [3][7]. - The interaction between OX40 and heparan sulfate activates key signaling pathways (AKT, MAPK, and NF-κB), enhancing cell adhesion and the functional affinity of CAR-T cells to tumor cells [7][10]. Group 2: Implications for CAR-T Therapy - CAR-T cells expressing OX40 demonstrate improved infiltration and persistence in solid tumors, relying on the interaction with heparan sulfate [8][10]. - The findings suggest that the OX40-heparan sulfate interaction can be leveraged to enhance CAR-T cell therapies for a broader range of solid tumors, opening new avenues for treatment strategies [10].